热线电话: 021-34661275
产品分类/PRODUCT CLASSIFICATION

上海细胞库

人源细胞系| 稳转细胞系| 基因敲除株| 基因点突变细胞株| 基因过表达细胞株| 重组细胞系| 猪的细胞系| 马细胞系| 兔的细胞系| 犬的细胞系| 山羊的细胞系| 鱼的细胞系| 猴的细胞系| 仓鼠的细胞系| 狗的细胞系| 牛的细胞| 大鼠细胞系| 小鼠细胞系| 其他细胞系|

原代细胞

原代细胞| 永生化细胞|

细胞培养

血清| 无血清冻存| 细胞培养试剂盒| 普通培养基| 完全培养基| 细胞污染预防| 细胞污染清除| 细胞培养辅助试剂|

细胞服务

STR鉴定服务| ATCC代购服务|

酶联试剂盒

人ELISA试剂盒| 大鼠ELISA试剂盒| 小鼠ELISA试剂盒| 兔ELISA试剂盒| 猪ELISA试剂盒| 鱼ELISA试剂盒| 牛ELISA试剂盒| 犬ELISA试剂盒| 鸭ELISA试剂盒| 豚鼠ELISA试剂盒| 鸡ELISA试剂盒| 绵羊ELISA试剂盒| 山羊ELISA试剂盒| 仓鼠ELISA试剂盒| 植物ELISA试剂盒| 药残留类试剂盒| 其他ELISA试剂盒|

生化试剂盒

生化试剂盒| 微量法检测盒| 分光法检测盒| 胶体金检测盒|

PCR试剂盒

荧光探针PCR试剂盒| 染料荧光PCR试剂盒| 核酸扩增/纯化| 普通PCR检测试剂盒| 质粒菌种感受态|

抗体蛋白

蛋白多肽| 抗体| 免疫组化| 免疫球蛋白|

试剂耗材

标准试液| 科研试剂| 缓 冲 液| 实验耗材| 高效液相色谱对照品|

首页 > 抗体蛋白 > 抗体
Brilliant Violet 510™ anti-mouse CD8a Antibo
产品名称：
Brilliant Violet 510™ anti-mouse CD8a Antibo
产品类别：
抗体
产品编号：
100751
产品应用：
100751
[价格]
规格 价格 库存
125µL ￥ 1980 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510? under optimal conditions.
Concentration
?g sizes: 0.2 mg/mL
?L sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the ?g size, the suggested use of this reagent is ≤0.5 ?g per million cells in 100 ?l volume. For immunofluorescent staining using the ?l size, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 510? excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 510? is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet?.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke?AJ,?et al.?2020.?Proc Natl Acad Sci U S A.?117:33455-65. (SB)?PubMed
  30. Radtke?AJ,?et al.?2022.?Nat Protoc.?17:378-401. (SB)?PubMed
Product Citations
  1. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  2. Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed
  3. Li SX, et al. 2019. PLoS Pathog. 15:e1007611. PubMed
  4. Wilfahrt D, et al. 2021. Elife. 10:. PubMed
  5. Otano I, et al. 2021. Nat Commun. 12:7296. PubMed
  6. Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed
  7. Kim S, et al. 2020. Immunity. 53(4):759-774.e9. PubMed
  8. Zhang LJ, et al. 2019. Immunity. 50:121. PubMed
  9. Baldwin SL, et al. 2021. PLoS One. 16:e0247990. PubMed
  10. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  11. Steubing RD, et al. 2022. Brain Behav Immun Health. 24:100493. PubMed
  12. Lino AC et al. 2018. Immunity. 49(1):120-133 . PubMed
  13. Wang D, et al. 2018. Immunity. 48:659. PubMed
  14. Larsen SE, et al. 2021. Sci Rep. 11:9040. PubMed
  15. Chen J, et al. 2022. J Nanobiotechnology. 20:283. PubMed
  16. Wang C, et al. 2015. Sci Rep. 5: 14124. PubMed
  17. Rodriguez-Ruiz M, et al. 2016. Cancer Res . 76: 5994 - 6005. PubMed
  18. Fuster JJ, et al. 2020. Cell Rep. 33:108326. PubMed
  19. Si Y, et al. 2020. Sci Adv. 6:eaba0995. PubMed
  20. Matsuoka S, et al. 2019. Haematologica. 105:226. PubMed
  21. Müller M, et al. 2021. Nat Commun. 12:7036. PubMed
  22. Gajdasik DW, et al. 2020. Nat Commun. 2.834027778. PubMed
  23. Jenkins RW, et al. 2018. Cancer Discov. 8:196. PubMed
  24. Tuttle KD, et al. 2020. Cell Rep. 33:108407. PubMed
  25. Dikiy S, et al. 2021. Immunity. 54(5):931-946.e11. PubMed
  26. Yang L, et al. 2021. Cell Death Differ. 28:2616. PubMed
  27. Flommersfeld S, et al. 2021. Immunity. :. PubMed
  28. Aegerter H, et al. 2020. Nat Immunol. 0.975694444. PubMed
  29. Lissner MM, et al. 2020. Elife. 9:00. PubMed
  30. Hiramoto T, et al. 2018. Mol Ther. 26:1255. PubMed
  31. Friedman DJ, et al. 2021. Cancer Immunol Res. 9:952. PubMed
  32. Knizkova D, et al. 2022. Nat Immunol. 23:1644. PubMed
  33. Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed
  34. Koivisto CS, et al. 2020. Neoplasia. 1.252777778. PubMed
  35. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  36. Telford W, et al. 2017. Cytometry A. 91:314. PubMed
  37. Leylek R, et al. 2019. Cell Rep. 29:3736. PubMed
  38. Yu X, et al. 2020. Cancer Cell. 37(6):850-866. PubMed
  39. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  40. Mulas F, et al. 2020. Cell Mol Immunol. . PubMed
  41. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  42. Liu CY, et al. 2020. Cell Rep. 33:108275. PubMed
  43. Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed
  44. Bradley KC, et al. 2019. Cell Rep. 28:245. PubMed
  45. Cosentino K, et al. 2022. Mol Cell. 82:933. PubMed
  46. Vogel A, et al. 2022. STAR Protoc. 3:101653. PubMed
  47. Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed
  48. Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed
  49. Kyburz A, et al. 2019. J Allergy Clin Immunol. 143:1496. PubMed
  50. Moore MJ et al. 2018. eLife. 7 pii: e33057. PubMed
  51. Souza SP, et al. 2021. PLoS Pathog. 17:e1010081. PubMed
  52. Ma X, et al. 2020. Immunity. 53:1315. PubMed
  53. van Vloten JP, et al. 2019. Mol Ther Methods Clin Dev. 13:154. PubMed
  54. Kyburz A, et al. 2017. Clin Exp Allergy. 47:1331. PubMed
  55. Cosway EJ, et al. 2017. J Exp Med. 214:3183. PubMed
  56. Ge C, et al. 2020. Cell Reports. 29(13):4236-4244.e3.. PubMed
  57. Loo CS, et al. 2020. Immunity. 53:143. PubMed
  58. Zhu D, et al. 2017. Stem Cell Res Ther. 0.511805556. PubMed
  59. Fowler AM et al. 2018. Cell host & microbe. 24(5):743-750 . PubMed
  60. Wang D, et al. 2022. EMBO Rep. 23:e53691. PubMed
  61. Tsai HI, et al. 2021. EMBO Mol Med. 13:e12834. PubMed
  62. Varikuti S, et al. 2020. Br J Cancer. 122:1005. PubMed
  63. Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed
  64. Soukup K, et al. 2017. Sci Rep. 10.1038/s41598-017-12208-7. PubMed
  65. Urata S, et al. 2018. PLoS Pathog. 14:e1007172. PubMed
  66. Mao W, et al. 2019. J Immunother Cancer. 0.484027778. PubMed
  67. Chen Y, et al. 2021. Nat Immunol. 22:996. PubMed
  68. Kim MY, et al. 2022. Nat Commun. 13:3296. PubMed
  69. Vogel A, et al. 2022. Cell Rep. 38:110420. PubMed
  70. Mairhofer D, et al. 2015. J Invest Dermatol. 135: 2785-93. PubMed
  71. Sun Y, et al. 2020. J Immunol. 205:2649. PubMed
  72. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  73. Tzeng TT, et al. 2022. NPJ Vaccines. 7:60. PubMed
  74. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
  75. Bommareddy PK, et al. 2019. J Biol Methods. 6:2. PubMed
  76. Schaftenaar FH, et al. 2019. Sci Rep. 9:17391. PubMed
  77. Tao Z, et al. 2022. Cells. 11:. PubMed
  78. McAusland TM, et al. 2021. Mol Ther Oncolytics. 20:306. PubMed
  79. Teijeira á, et al. 2020. Immunity. 52(5):856-871. PubMed
  80. Rappe JCF, et al. 2021. J Exp Med. 218:. PubMed
  81. Wang T, et al. 2015. Proc Natl Acad Sci U S A. 112:440. PubMed
  82. Wang X, et al. 2021. Immunity. 54(6):1123-1136.e8. PubMed
  83. Jiang W, et al. 2021. Cell Rep. 37:110112. PubMed
  84. Zhang L, et al. 2021. Mol Ther. 29:744. PubMed
  85. Liu Y, et al. 2021. Nat Commun. 12:6831. PubMed
  86. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
RRID
AB_2561389 (BioLegend Cat. No. 100751) AB_2563057 (BioLegend Cat. No. 100752)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8a on UniProt.org

联系我们

TEL：021-34661275 　点击拨打热线